Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J06 IMMUNE SERA AND IMMUNOGLOBULINS
J06B IMMUNOGLOBULINS
J06BD Antiviral monoclonal antibodies
J06BD03 Tixagevimab and cilgavimab
D12262 Tixagevimab and cilgavimab <JP>
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D12262 Tixagevimab and cilgavimab
Drug groups [BR:br08330]
Antiviral
DG03174 Anti-SARS-CoV-2 agent
D12262 Tixagevimab and cilgavimab
Drug classes [BR:br08332]
Antiviral
DG03174 Anti-SARS-CoV-2 agent
D12262 Tixagevimab and cilgavimab
Antimicrobials [BR:br08307]
Antivirals
Entry, fusion or uncoating inhibitor
Coronavirus spike protein
D12262 Tixagevimab and cilgavimab <JP>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12262
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D12262
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12262